« Previous
Next »
Titles
- REMS: FDA's application of statutory factors in determining when a REMS is necessary1
- Rabbits, drawn from life (prize specimens). Horses, drawn from life (prize specimens)1
- Racial and ethnic differences in children's mental health services in Medicaid before and during the COVID-19 pandemic1
- Racial and ethnic health disparities1
- Raising the bar: impacts and implementation of the New Heights Program for expectant and parenting teens in Washington, DC1
- Rare diseases: Although limited, available evidence suggests medical and other costs can be substantial : report to congressional committees1
- Rare diseases: considerations for the development of drugs and biological products : guidance for industry1
- Reaching the remaining uninsured: an evidence review on outreach & enrollment1
- Read it before you eat it!1
- Real-time oncology review (RTOR): guidance for industry1
- Real-world data: assessing registries to support regulatory decision-making for drug and biological products : guidance for industry1
- Rebalancing long-term care: the role of the Medicaid HCBS waiver program1
- Rebates for brand-name drugs in Part D substantially reduced the growth in spending from 2011 to 20151
- Recognition and withdrawal of voluntary consensus standards: guidance for industry and Food and Drug Administration staff1
- Recommendation followup: vulnerabilities continue to exist in the HHS small business innovation research program1
- Recommendations for clinical laboratory improvement amendments of 1988 (CLIA) waiver applications for manufacturers of in vitro diagnostic devices: guidance for industry and Food and Drug Administration staff1
- Recommendations for dual 510(k) and CLIA waiver by application studies: guidance for industry and Food and Drug Administration staff1
- Recommendations for evaluating donor eligibility using individual risk-based questions to reduce the risk of human immunodeficiency virus transmission by blood and blood products: guidance for industry1
- Recommendations for reducing the risk of transfusion-transmitted babesiosis1
- Recommendations to reduce the possible risk of transmission of Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease by blood and blood components2